A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) (GALLEGO)

NCT03972709 PHASE2 TERMINATED Results posted

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control. After completing the study's last visit (Week 76), eligible participants will have the option to enroll in open-label extension study NCT04607148 (GR42558) and receive open-label galegenimab (FHTR2163) injections.

Details

Lead sponsor	Genentech, Inc.
Phase	PHASE2
Status	TERMINATED
Enrolment	372
Start date	Mon Jun 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Macular Degeneration, Age-Related
• Geographic Atrophy

Interventions

• Galegenimab
• Sham Control

Countries

United States